INS and metabolic dysfunction-associated steatotic liver disease: While MASLD is characterized by increased fat accumulation, impaired mitochondrial activity, higher oxidative stress, inflammation, and reduced insulin sensitivity, the MD works in the opposite direction, such as by improving insulin sensitivity, lowering liver fat production, reducing inflammation and oxidative damage, and supporting healthier gut microbiota.